Rusfertide for Patients With Phlebotomy-Dependent Polycythemia Vera
Rusfertide demonstrated activity in reducing hematocrit levels in patients with polycythemia vera in two phase 2 clinical trials.
Diagnosis & Disease Information
Factors Related to Adherence to Oral Multiple Myeloma Therapy
Researchers sought to identify socioeconomic and demographic factors related to adherence to oral therapies in patients with multiple myeloma.
Patient-Reported Outcomes and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation
Researchers sought to find whether there was a relationship between patient-reported outcomes and overall survival after hematopoietic stem cell transplantation.
Post-Transplant Carfilzomib, Lenalidomide, and Dexamethasone May Be New Standard of Care in Multiple Myeloma
Researchers sought to determine whether post-transplant carfilzomib, lenalidomide, and dexamethasone would have superior PFS in patients with multiple myeloma.
Momelotinib Demonstrates Superiority Over Danazol in Thrombocytopenic Myelofibrosis
Researchers sought to compare the efficacy of momelotinib with danazol in patients with thrombocytopenic myelofibrosis who were symptomatic and anemic.
Fixed Combination Decitabine/Cedazuridine Plus Venetoclax Feasible in Acute Myeloid Leukemia
Researchers sought to determine whether ASTX727 with venetoclax would be effective in patients with AML.
Modest Efficacy Seen With Tislelizumab in T-Cell and NK-Cell Lymphomas
Researchers sought to determine whether tislelizumab would be an effective treatment for patients with relapsed/refractory mature T/NK-cell lymphomas.
Zanubrutinib May Improve Response Rate Compared With Ibrutinib in Waldenström Macroglobulinemia
Researchers sough to determine whether zanubrutinib would improve responses compared with ibrutinib in patients with Waldenström macroglobulinemia.
Momelotinib May Improve Some Outcomes Vs Danazol in Myelofibrosis
Researchers sought to determine whether momelotinib would improve outcomes in patients with anemic myelofibrosis compared with danazol.
The Effect of Gender Bias in Surveys of Patients With Myeloproliferative Neoplasm
Gender balance in cancer surveys of patients with myeloproliferative neoplasms was found to have relatively little effect on survey outcomes.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...